Phase 1 N=12 Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
Parkinson Disease
Primary: Mean Peak Dyskinesia Score — 11.00; 11.42; 8.50 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Healthy Volunteers
Primary: Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban — 190.873; 181.862; 153.693 ng/mL
Phase 1 N=20 A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) — 780; 717; 858 nanograms*hours/milliliter (ng*hr/mL)
Phase 1 N=44 Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Assessment of Maximum Plasma Concentration (Cmax) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291 — 13.96; 24.03 nanogram per millilitre (ng/mL)
Phase 1 N=25 Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
Neoplasms, · Metastatic Cancer, · Non-Small Cell Lung Cancer
Primary: Cmax of Selumetinib After Single Dose — 2534; 1073; 370.3; 897.1 ng/mL
Phase 1 N=39 Phase 1, TAK-648, Single-Rising Dose Study
Healthy Volunteers
Primary: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE) — 0; 50.0; 16.7; 0 percentage of participants
Phase 1 N=48 Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 41.7; 33.3; 16.7; 33.3 percentage of participants
Phase 1 N=190 A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis
Allergic Rhinitis
Primary: Percentages of Participants With Local Reactions By Severity Within 14 Days of Any Vaccination — 50.0; 9.5; 30.0; 15.0 Percentage of participants
Phase 1 N=67 Effect of Intensified Physical Activity for Patients With Stroke - a Combined Physical and Behavioural Approach
Stroke
Primary: The Berg Balance Scale (BBS) — -0.06; 4.1; 0.8; 2.3 units on a scale — p=0.001
Phase 1 N=10 Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)
Pulmonary Disease, Chronic Obstructive
Primary: Area Under the Concentration Versus Time Curve (AUClast) — 686.98; 1247.63; 1769.58 h*pg/mL
Phase 1 N=16 A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance
Healthy Volunteer
Primary: Total Dialysate Clearance for Automated Peritoneal Dialysis (CLDAPD) of Oseltamivir and Oseltamivir Carboxylate for 75 mg Dose — NA; NA; 0.183; 0.230 Litre (L)/hour (h)
Phase 1 N=20 A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants
Healthy Volunteer
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Cobimetinib — 778; 864; 846 nanograms*hours/milliliter (ng*hr/mL)
Phase 1 N=52 A Bioequivalence Study of TAK-536 Pediatric Formulation
Japanese Healthy Adult Males
Primary: AUC(0-48): Area Under the Plasma Concentration-Time Curve From Time 0 to 48 Hours Postdose for TAK-536 in Dry Syrup Cohort — 7065.6; 7341.2 nanogram*hour per milliliter…
Phase 1 N=26 Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Phase 1 N=12 Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
Osteoarthritis, Knee
Primary: Summary of Adverse Events — 2; 2; 3; 2 Adverse events